Drug intelligence / Profile preview

fedovapagon

Development stage: Phase 3
Lead developer: Vantia
Modality: Small Molecules
Administration: Oral

Overview

Fedovapagon is a selective, orally active, nonpeptidic small molecule agonist of the vasopressin V2 receptor (V2R). It was developed for the treatment of nocturia and related bladder disorders. By activating the V2 receptor in the kidney, fedovapagon increases water reabsorption and reduces urine output. Clinical studies have shown dose-dependent antidiuretic effects with reliable pharmacodynamic responses. The drug was originally discovered by Vantia Therapeutics and reached up to phase II/III clinical trials for nocturia before development was discontinued[1][3][4][6][7].

Brand names: fedovapagon
Other names: fedovapagon [INN]347887-36-9UNII-VX2GBO4I0VUNII-VX-2GBO4I0VUNII-VX 2GBO4I0VVX2GBO4I0VVX-2GBO4I0VVX 2GBO4I0VCHEMBL518043CHEMBL-518043CHEMBL 518043

Targets

AVPR2 (Arginine vasopressin V2 receptor)

Beyond the preview

Go deeper on fedovapagon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fedovapagon.

Explore the full profile